The Impact of Autoimmunity on Hepatocytes

ABSTRACT

In this article, the impact of autoimmunity on the hepatocyte is analyzed in three distinct settings: classical autoimmune hepatitis, chronic hepatitis C virus infection with autoimmune manifestations, and de novo autoimmune hepatitis after liver transplantation. (1) Classical autoimmune hepatitis: Using as model autoimmune hepatitis type 2, whose main autoantigen is known, complementary aspects of the autoimmune response are revisited, including the targeting of discrete antigenic regions by humoral and cellular effectors of damage and a defect in the counterbalancing immunoregulatory mechanisms. (2) Chronic hepatitis C virus infection: This condition provides clues to the possible role of viruses as triggers of autoimmunity. The interaction between hepatitis C virus and its receptor on B lymphocytes is the likely trigger of a polyclonal activation leading to the production of autoantibodies. These appear not to be an epiphenomenon but to be markers of hepatocyte damage. (3) De novo autoimmune hepatitis after liver transplantation: The intriguing observation that autoimmune hepatitis can arise de novo after liver transplantation is presented and its possible pathogenic mechanisms are discussed.

KEYWORDS

Autoimmune hepatitis - T regulatory cells - autoreactive T cells - autoantibodies - hepatitis C virus infection

REFERENCES

• 1 Johnson P J, McFarlane I G. Meeting report: International Autoimmune Hepatitis Group.  Hepatology. 1993;  18 998-1005
• 2 Alvarez F, Berg P A, Bianchi F B et al.. International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis.  J Hepatol. 1999;  31 929-938
• 3 Vergani D, Alvarez F, Bianchi F B et al.. Liver autoimmune serology: a consensus statement from the committee for autoimmune serology of the International Autoimmune Hepatitis Group.  J Hepatol. 2004;  41 677-683
• 4 Muratori L, Parola M, Ripalti A et al.. Liver/kidney microsomal antibody type 1 targets CYP2D6 on hepatocyte plasma membrane.  Gut. 2000;  46 553-561
• 5 Ma Y, Okamoto M, Thomas M G et al.. Antibodies to conformational epitopes of soluble liver antigen define a severe form of autoimmune liver disease.  Hepatology. 2002;  35 658-664
• 6 Wen L, Ma Y, Bogdanos D P et al.. Pediatric autoimmune liver diseases: the molecular basis of humoral and cellular immunity.  Curr Mol Med. 2001;  1 379-389
• 7 Senaldi G, Portmann B, Mowat A P, Mieli-Vergani G, Vergani D. Immunohistochemical features of the portal tract mononuclear cell infiltrate in chronic aggressive hepatitis.  Arch Dis Child. 1992;  67 1447-1453
• 8 Weaver C T, Harrington L E, Mangan P R, Gavrieli M, Murphy K M. Th17: an effector CD4 + T cell lineage with regulatory T cell ties.  Immunity. 2006;  24 677-688
• 9 Steinman L. A brief history of T(H)17, the first major revision in the T(H)1/T(H)2 hypothesis of T cell-mediated tissue damage.  Nat Med. 2007;  13 139-145
• 10 Nouri-Aria K T, Donaldson P T, Hegarty J E, Eddleston A L, Williams R. HLA A1-B8-DR3 and suppressor cell function in first-degree relatives of patients with autoimmune chronic active hepatitis.  J Hepatol. 1985;  1 235-241
• 11 Nouri-Aria K T, Hegarty J E, Alexander G J, Eddleston A L, Williams R. Effect of corticosteroids on suppressor-cell activity in “autoimmune” and viral chronic active hepatitis.  N Engl J Med. 1982;  307 1301-1304
• 12 Cortesini R, LeMaoult J, Ciubotariu R, Cortesini N S. CD8 + CD28 - T suppressor cells and the induction of antigen-specific, antigen-presenting cell-mediated suppression of Th reactivity.  Immunol Rev. 2001;  182 201-206
• 13 Vento S, Hegarty J E, Bottazzo G, Macchia E, Williams R, Eddleston A L. Antigen specific suppressor cell function in autoimmune chronic active hepatitis.  Lancet. 1984;  1 1200-1204
• 14 Shevach E M, McHugh R S, Piccirillo C A, Thornton A M. Control of T cell activation by CD4 + CD25 + suppressor T cells.  Immunol Rev. 2001;  182 58-67
• 15 Longhi M S, Ma Y, Bogdanos D P, Cheeseman P, Mieli-Vergani G, Vergani D. Impairment of CD4( + )CD25( + ) regulatory T cells in autoimmune liver disease.  J Hepatol. 2004;  41 31-37
• 16 Longhi M S, Hussain M J, Mitry R R et al.. Functional study of CD4 + CD25 + regulatory T cells in health and autoimmune hepatitis.  J Immunol. 2006;  176 4484-4491
• 17 Longhi M S, Ma Y, Mitry R R et al.. Effect of CD4 + CD25 + regulatory T cells on CD8 T cell function in patients with autoimmune hepatitis.  J Autoimmun. 2005;  25 63-71
• 18 Ma Y, Bogdanos D P, Hussain M J et al.. Polyclonal T cell responses to cytochrome P450IID6 are associated with disease activity in autoimmune hepatitis type 2.  Gastroenterology. 2006;  130 868-882
• 19 Lobo-Yeo A, Alviggi L, Mieli-Vergani G, Portmann B, Mowat A P, Vergani D. Preferential activation of helper/inducer T lymphocytes in autoimmune chronic active hepatitis.  Clin Exp Immunol. 1987;  67 95-104
• 20 Wen L, Peakman M, Lobo-Yeo A et al.. T cell-directed hepatocyte damage in autoimmune chronic active hepatitis.  Lancet. 1990;  336 1527-1530
• 21 Rizzetto M, Swana G, Doniach D. Microsomal antibodies in active chronic hepatitis and other disorders.  Clin Exp Immunol. 1973;  15 331-344
• 22 Alvarez F, Bernard O, Homberg J C, Kreibich G. Anti-liver-kidney microsome antibody recognizes a 50,000 molecular weight protein of the endoplasmic reticulum.  J Exp Med. 1985;  161 1231-1236
• 23 Waxman D J, Lapenson D P, Krishnan M, Bernard O, Kreibich G, Alvarez F. Antibodies to liver/kidney microsome1 in chronic active hepatitis recognize specific forms of hepatic cytochrome P-450.  Gastroenterology. 1988;  95 1326-1331
• 24 Zanger U M, Hauri H P, Loeper J, Homberg J C, Meyer U A. Antibodies against human cytochrome P-450db1 in autoimmune hepatitis type II.  Proc Natl Acad Sci USA. 1988;  85 8256-8260
• 25 Gueguen M, Meunier-Rotival M, Bernard O, Alvarez F. Anti-liver kidney microsome antibody recognizes a cytochrome P450 from the IID subfamily.  J Exp Med. 1988;  168 801-806
• 26 Manns M P, Johnson E F, Griffin K J, Tan E M, Sullivan K F. Major antigen of liver kidney microsomal autoantibodies in idiopathic autoimmune hepatitis is cytochrome P450db1.  J Clin Invest. 1989;  83 1066-1072
• 27 Manns M P, Griffin K J, Sullivan K F, Johnson E F. LKM-1 autoantibodies recognize a short linear sequence in P450IID6, a cytochrome P-450 monooxygenase.  J Clin Invest. 1991;  88 1370-1378
• 28 Kerkar N, Choudhuri K, Ma Y et al.. Cytochrome P4502D6(193-212): a new immunodominant epitope and target of virus/self cross-reactivity in liver kidney microsomal autoantibody type 1-positive liver disease.  J Immunol. 2003;  170 1481-1489
• 29 Ma Y, Thomas M G, Okamoto M et al.. Key residues of a major cytochrome P4502D6 epitope are located on the surface of the molecule.  J Immunol. 2002;  169 277-285
• 30 Peakman M, Lobo-Yeo A, Mieli-Vergani G, Davies E T, Mowat A P, Vergani D. Characterization of anti-liver kidney microsomal antibody in childhood autoimmune chronic active hepatitis: evidence for IgG1 subclass restriction, polyclonality and non cross-reactivity with hepatocyte surface antigens.  Clin Exp Immunol. 1987;  69 543-549
• 31 Lohr H F, Schlaak J F, Lohse A W et al.. Autoreactive CD4 + LKM-specific and anticlonotypic T cell responses in LKM-1 antibody-positive autoimmune hepatitis.  Hepatology. 1996;  24 1416-1421
• 32 Battaglia M, Gregori S, Bacchetta R, Roncarolo M G. Tr1 cells: from discovery to their clinical application.  Semin Immunol. 2006;  18 120-127
• 33 Lohr H, Manns M, Kyriatsoulis A et al.. Clonal analysis of liver-infiltrating T cells in patients with LKM-1 antibody-positive autoimmune chronic active hepatitis.  Clin Exp Immunol. 1991;  84 297-302
• 34 Longhi M S, Hussain M J, Bogdanos D P et al.. Cytochrome P450IID6-specific effector CD8 T cell immune responses mirror disease activity in autoimmune hepatitis type 2.  Hepatology. 2007;  , In press
• 35 Matsumura S, Kita H, He X S et al.. Comprehensive mapping of HLA-A0201-restricted CD8 T cell epitopes on PDC-E2 in primary biliary cirrhosis.  Hepatology. 2002;  36 1125-1134
• 36 Reijonen H, Elliott J F, van Endert P, Nepom G. Differential presentation of glutamic acid decarboxylase 65 (GAD65) T cell epitopes among HLA-DRB1*0401-positive individuals.  J Immunol. 1999;  163 1674-1681
• 37 Trotter J L, Pelfrey C M, Trotter A L et al.. T cell recognition of myelin proteolipid protein and myelin proteolipid protein peptides in the peripheral blood of multiple sclerosis and control subjects.  J Neuroimmunol. 1998;  84 172-178
• 38 Kita H, Matsumura S, He X S et al.. Quantitative and functional analysis of PDC-E2-specific autoreactive cytotoxic T lymphocytes in primary biliary cirrhosis.  J Clin Invest. 2002;  109 1231-1240
• 39 Roth E, Pircher H. IFN-gamma promotes Fas ligand- and perforin-mediated liver cell destruction by cytotoxic CD8 T cells.  J Immunol. 2004;  172 1588-1594
• 40 Guy C S, Wang J, Michalak T I. Hepatocytes as cytotoxic effector cells can induce cell death by CD95 ligand-mediated pathway.  Hepatology. 2006;  43 1231-1240
• 41 Ando K, Moriyama T, Guidotti L G et al.. Mechanisms of class I restricted immunopathology: a transgenic mouse model of fulminant hepatitis.  J Exp Med. 1993;  178 1541-1554
• 42 Vergani D. LKM antibody: getting in some target practice.  Gut. 2000;  46 449-450
• 43 Pileri P, Uematsu Y, Campagnoli S et al.. Binding of hepatitis C virus to CD81.  Science. 1998;  282 938-941
• 44 Levy S, Shoham T. The tetraspanin web modulates immune-signalling complexes.  Nat Rev Immunol. 2005;  5 136-148
• 45 Rosa D, Saletti G, De Gregorio E et al.. Activation of naive B lymphocytes via CD81, a pathogenetic mechanism for hepatitis C virus-associated B lymphocyte disorders.  Proc Natl Acad Sci USA. 2005;  102 18544-18549
• 46 Pal S, Sullivan D G, Kim S et al.. Productive replication of hepatitis C virus in perihepatic lymph nodes in vivo: implications of HCV lymphotropism.  Gastroenterology. 2006;  130 1107-1116
• 47 Dickson R C. Clinical manifestations of hepatitis C.  Clin Liver Dis. 1997;  1 569-585
• 48 Bellentani S, Tiribelli C, Saccoccio G et al.. Prevalence of chronic liver disease in the general population of northern Italy: the Dionysos Study.  Hepatology. 1994;  20 1442-1449
• 49 Lenzi M, Bellentani S, Saccoccio G et al.. Prevalence of non-organ-specific autoantibodies and chronic liver disease in the general population: a nested case-control study of the Dionysos cohort.  Gut. 1999;  45 435-441
• 50 Giostra F, Manzin A, Lenzi M et al.. Low hepatitis C viremia levels in patients with anti-liver/kidney microsomal antibody type 1 positive chronic hepatitis.  J Hepatol. 1996;  25 433-438
• 51 Muratori L, Lenzi M, Cataleta M et al.. Interferon therapy in liver/kidney microsomal antibody type 1-positive patients with chronic hepatitis C.  J Hepatol. 1994;  21 199-203
• 52 Todros L, Saracco G, Durazzo M et al.. Efficacy and safety of interferon alfa therapy in chronic hepatitis C with autoantibodies to liver-kidney microsomes.  Hepatology. 1995;  22 1374-1378
• 53 Muratori P, Czaja A J, Muratori L et al.. Evidence of a genetic basis for the different geographic occurrences of liver/kidney microsomal antibody type 1 in hepatitis C.  Dig Dis Sci. 2007;  52 179-184
• 54 Bogdanos D P, Lenzi M, Okamoto M et al.. Multiple viral/self immunological cross-reactivity in liver kidney microsomal antibody positive hepatitis C virus infected patients is associated with the possession of HLA b51.  Int J Immunopathol Pharmacol. 2004;  17 83-92
• 55 Muratori L, Bogdanos D P, Muratori P et al.. Susceptibility to thyroid disorders in hepatitis C.  Clin Gastroenterol Hepatol. 2005;  3 595-603
• 56 Kerkar N, Hadzic N, Davies E T et al.. De-novo autoimmune hepatitis after liver transplantation.  Lancet. 1998;  351 409-413
• 57 Andries S, Casamayou L, Sempoux C et al.. Posttransplant immune hepatitis in pediatric liver transplant recipients: incidence and maintenance therapy with azathioprine.  Transplantation. 2001;  72 267-272
• 58 Gupta P, Hart J, Millis J M, Cronin D, Brady L. De novo hepatitis with autoimmune antibodies and atypical histology: a rare cause of late graft dysfunction after pediatric liver transplantation.  Transplantation. 2001;  71 664-668
• 59 Heneghan M A, Portmann B C, Norris S M et al.. Graft dysfunction mimicking autoimmune hepatitis following liver transplantation in adults.  Hepatology. 2001;  34 464-470
• 60 Hernandez H M, Kovarik P, Whitington P F, Alonso E M. Autoimmune hepatitis as a late complication of liver transplantation.  J Pediatr Gastroenterol Nutr. 2001;  32 131-136
• 61 Spada M, Bertani A, Sonzogni A et al.. A cause of late graft dysfunction after liver transplantation in children: de-novo autoimmune hepatitis.  Transplant Proc. 2001;  33 1747-1748
• 62 Dunn M J, Crisp S J, Rose M L, Taylor P M, Yacoub M H. Anti-endothelial antibodies and coronary artery disease after cardiac transplantation.  Lancet. 1992;  339 1566-1570
• 63 Dunn M J, Rose M L, Latif N et al.. Demonstration by western blotting of antiheart antibodies before and after cardiac transplantation.  Transplantation. 1991;  51 806-812
• 64 Joyce S, Mathew J M, Flye M W, Mohanakumar T. A polymorphic human kidney-specific non-MHC alloantigen: its possible role in tissue-specific allograft immunity.  Transplantation. 1992;  53 1119-1127
• 65 Dubel L, Farges O, Sato Y, Bismuth H. Development of anti-tissue antibodies in the rat liver transplant model.  Transplantation. 1998;  65 1135-1137
• 66 Fedoseyeva E V, Tam R C, Popov I A, Orr P L, Garovoy M R, Benichou G. Induction of T cell responses to a self-antigen following allotransplantation.  Transplantation. 1996;  61 679-683
• 67 Fedoseyeva E V, Zhang F, Orr P L, Levin D, Buncke H J, Benichou G. De novo autoimmunity to cardiac myosin after heart transplantation and its contribution to the rejection process.  J Immunol. 1999;  162 6836-6842
• 68 Dubel L, Farges O, Johanet C, Sebagh M, Bismuth H. High incidence of antitissue antibodies in patients experiencing chronic liver allograft rejection.  Transplantation. 1998;  65 1072-1075
• 69 Salcedo M, Pons J A, Sousa J M et al.. De novo autoimmune hepatitis after liver transplantation.  J Hepatol. 2001;  34 49 , (Abstract)
• 70 Evans H M, Kelly D A, McKiernan P J, Hubscher S. Progressive histological damage in liver allografts following pediatric liver transplantation.  Hepatology. 2006;  43 1109-1117
• 71 Salcedo M, Vaquero J, Banares R et al.. Response to steroids in de novo autoimmune hepatitis after liver transplantation.  Hepatology. 2002;  35 349-356
• 72 Bogdanos D P, Choudhuri K, Vergani D. Molecular mimicry and autoimmune liver disease: virtuous intentions, malign consequences.  Liver. 2001;  21 225-232
• 73 Gao E K, Lo D, Cheney R, Kanagawa O, Sprent J. Abnormal differentiation of thymocytes in mice treated with cyclosporin A.  Nature. 1988;  336 176-179
• 74 Bucy R P, Xu X Y, Li J, Huang G. Cyclosporin A-induced autoimmune disease in mice.  J Immunol. 1993;  151 1039-1050
• 75 Wu D Y, Goldschneider I. Cyclosporin A-induced autologous graft-versus-host disease: a prototypical model of autoimmunity and active (dominant) tolerance coordinately induced by recent thymic emigrants.  J Immunol. 1999;  162 6926-6933
• 76 Damoiseaux J G, Beijleveld L J, van Breda Vriesman P J. Multiple effects of cyclosporin A on the thymus in relation to T cell development and autoimmunity.  Clin Immunol Immunopathol. 1997;  82 197-202
• 77 Sakaguchi S, Sakaguchi N. Role of genetic factors in organ-specific autoimmune diseases induced by manipulating the thymus or T cells, and not self-antigens.  Rev Immunogenet. 2000;  2 147-153
• 78 Aguilera I, Wichmann I, Sousa J M et al.. Antibodies against glutathione S-transferase T1 (GSTT1) in patients with de novo immune hepatitis following liver transplantation.  Clin Exp Immunol. 2001;  126 535-539
• 79 Aguilera I, Sousa J M, Gavilan F, Bernardos A, Wichmann I, Nunez-Roldan A. Glutathione S-transferase T1 mismatch constitutes a risk factor for de novo immune hepatitis after liver transplantation.  Liver Transpl. 2004;  10 1166-1172
• 80 Aguilera I, Wichmann I, Gentil M A, Gonzalez-Escribano F, Nunez-Roldan A. Alloimmune response against donor glutathione S-transferase T1 antigen in renal transplant recipients.  Am J Kidney Dis. 2005;  46 345-350